6533b855fe1ef96bd12b0003

RESEARCH PRODUCT

Algorithmically deduced FREM2 molecular pathway is a potent grade and survival biomarker of human gliomas

Alf GieseVictor TkachevAndrew GarazhaAnton BuzdinAlexey MoisseevAlja ZottelElla KimMarianna ZolotovskaiaMarianna ZolotovskaiaSven R. KantelhardtDenis KuzminBettina SprangSven-ernö BikarNeja ŠAmecVictor EfimovIvana JovčevskaMaxim SorokinMaxim Sorokin

subject

Cancer ResearchMutantnapoved preživetjaBiologyTranscriptometranscriptomicsGliomagliomagliommedicineGeneRC254-282udc:616-006glioblastomWild typeglioblastomaNeoplasms. Tumors. Oncology. Including cancer and carcinogenssurvival prognosisMolecular pathway<i>FREM2</i>medicine.diseasenervous system diseasesOncologyCancer researchBiomarker (medicine)algorithmically deduced molecular pathwayFREM2Glioblastoma

description

Gliomas are the most common malignant brain tumors with high mortality rates. Recently we showed that the FREM2 gene has a role in glioblastoma progression. Here we reconstructed the FREM2 molecular pathway using the human interactome model. We assessed the biomarker capacity of FREM2 expression and its pathway as the overall survival (OS) and progression-free survival (PFS) biomarkers. To this end, we used three literature and one experimental RNA sequencing datasets collectively covering 566 glioblastomas (GBM) and 1097 low-grade gliomas (LGG). The activation level of deduced FREM2 pathway showed strong biomarker characteristics and significantly outperformed the FREM2 expression level itself. For all relevant datasets, it could robustly discriminate GBM and LGG (p &lt

yearjournalcountryeditionlanguage
2021-08-16
10.3390/cancers13164117https://hdl.handle.net/20.500.12556/RUL-135973